News & Updates

Show Multimedia Only

Fertility treatment may be less effective in COVID-infected couples

03 Aug 2023 by

Couples infected with SARS-CoV-2 while receiving assisted reproductive technology (ART) treatment had lower quality embryo and blastocyst rates compared with uninfected couples in a multicentre cohort study.

Fertility treatment may be less effective in COVID-infected couples

03 Aug 2023

Abrocitinib effectively controls AD regardless of dosing regimen

03 Aug 2023 by

In patients with moderate-to-severe atopic dermatitis (AD), flexible dosing of abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, appeared as beneficial as the continuous high-dose regimen. This was demonstrated in a post hoc analysis of two studies from the JADE* clinical development programme.

Abrocitinib effectively controls AD regardless of dosing regimen

03 Aug 2023

Awareness is key to preventing lipohypertrophy in diabetic patients on insulin

03 Aug 2023 by

A study on adult patients with type 2 diabetes mellitus (T2DM) treated with insulin for at least 6 months showed 2-in-5 patients had lipohypertrophy.

Awareness is key to preventing lipohypertrophy in diabetic patients on insulin

03 Aug 2023

Dupilumab confers benefit in bullous pemphigoid

02 Aug 2023 by

The monoclonal antibody dupilumab, alone or in combination with conventional agents, appeared to effectively control bullous pemphigoid (BP), a study from China has shown.

Dupilumab confers benefit in bullous pemphigoid

02 Aug 2023

Original New Drug Application Approvals by US FDA (16-31 July 2023)

02 Aug 2023

New drug applications approved by US FDA as of 16-31 July 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 July 2023)

02 Aug 2023

PPI use carries increased risk of pneumonia

01 Aug 2023

Individuals who use proton pump inhibitors (PPIs) appear to be at heightened risk of pneumonia, as reported in a study.

PPI use carries increased risk of pneumonia

01 Aug 2023

Common glucose-lowering drug may also work to prevent muscle atrophy in older adults

01 Aug 2023 by

For older people, administering metformin before or during a period of reduced physical activity appears to have potential benefits for the muscles, such as reducing atrophy and improving recovery, as reported by a team of US-based researchers.

Common glucose-lowering drug may also work to prevent muscle atrophy in older adults

01 Aug 2023

Novel oral IL-23R antagonist improves skin lesions in patients with plaque psoriasis

01 Aug 2023 by

Treatment with JNJ-77242113, an oral interleukin-23 receptor (IL-23R) antagonist peptide, leads to significant improvement in skin lesions, as measured by the Psoriasis Area and Severity Index (PASI) scores, in patients with moderate-to-severe plaque psoriasis, according to the FRONTIER 1 study presented at WCD 2023.

Novel oral IL-23R antagonist improves skin lesions in patients with plaque psoriasis

01 Aug 2023

Which factor predicts successful interval extension in eyes with nAMD switched to brolucizumab?

31 Jul 2023

In patients with neovascular age-related macular degeneration (nAMD) who switched to brolucizumab treatment, those with shorter treatment interval before switching are more likely to have successful injection interval extension, as shown in a study.

Which factor predicts successful interval extension in eyes with nAMD switched to brolucizumab?

31 Jul 2023

Phase II data underpin potential of novel triplet for cystic fibrosis

31 Jul 2023 by

Two phase II studies showed favourable signals for vanzacaftor, tezacaftor, and deutivacaftor (VX-121/TEZ/D-IVA) – a novel triplet regimen for cystic fibrosis (CF) – which could be an alternative to elexacaftor, tezacaftor, and ivacaftor (ELX/TEZ/IVA).

Phase II data underpin potential of novel triplet for cystic fibrosis

31 Jul 2023

News & Updates

Filter by Specialty:

Specialty:

Fertility treatment may be less effective in COVID-infected couples

Fertility treatment may be less effective in COVID-infected couples

Abrocitinib effectively controls AD regardless of dosing regimen

Abrocitinib effectively controls AD regardless of dosing regimen

Awareness is key to preventing lipohypertrophy in diabetic patients on insulin

Awareness is key to preventing lipohypertrophy in diabetic patients on insulin

Dupilumab confers benefit in bullous pemphigoid

Dupilumab confers benefit in bullous pemphigoid

Original New Drug Application Approvals by US FDA (16-31 July 2023)

Original New Drug Application Approvals by US FDA (16-31 July 2023)

PPI use carries increased risk of pneumonia

PPI use carries increased risk of pneumonia

Common glucose-lowering drug may also work to prevent muscle atrophy in older adults

Common glucose-lowering drug may also work to prevent muscle atrophy in older adults

Novel oral IL-23R antagonist improves skin lesions in patients with plaque psoriasis

Novel oral IL-23R antagonist improves skin lesions in patients with plaque psoriasis

Which factor predicts successful interval extension in eyes with nAMD switched to brolucizumab?

Which factor predicts successful interval extension in eyes with nAMD switched to brolucizumab?

Phase II data underpin potential of novel triplet for cystic fibrosis

Phase II data underpin potential of novel triplet for cystic fibrosis